Nutra Pharma is a biopharmaceutical company that develops and sells homeopathic pain relief products derived from diluted Asian cobra venom. Its commercial business centers on the Nyloxin brand, available as a topical gel and oral spray for chronic pain. Nutra Pharma markets these products as non-opioid and non-NSAID alternatives and offers specialized versions for pets and horses. Nutra Pharma sells through its own websites, online marketplaces like Amazon and Walmart, and physician offices. Nutra Pharma manufactures its products at an in-house facility in Florida and provides contract manufacturing for third-party private-label brands. Nutra Pharma also maintains a pre-revenue pipeline of drug candidates, including RPI-78M for multiple sclerosis and RPI-MN for viral diseases. These candidates currently lack FDA approval. Nutra Pharma's strategy includes expanding international distribution and advancing clinical trials, though these initiatives depend on securing external financing. Nutra Pharma operates with a limited workforce and faces persistent capital constraints that restrict its marketing and development activities.